In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent expiration has little effect on drug utilization especially when those drugs are delivered through insurance plans. This paper provides a quantitative model consistent with the theory and evidence in which pharmacy benefit management on behalf of insurance plans serves these and other purposes in both monopoly and oligopoly provider settings. Calibrating the model to the U.S. market, I conclude that pharmacy benefit management is worth at least $145 billion annually beyond its resource costs. PBM services add at least $192 billion annually in value to society compared to a manufacturer price-control regime. Requiring all PBM services to be self-provided by plan sponsors would forgo about 40 percent of the net value of PBM services largely by increasing management costs. Due to changes in the incidence of PBM services over the drug life cycle, the services encourage innovation even though they reduce the profits of incumbent manufacturers.

More on this topic

BFI Working Paper·Apr 23, 2025

Evaluating Recent Crackdowns on Disability Benefits: Effects on Income and Health Care Use in Australia

Manasi Deshpande, Greg Kaplan, and Tobias Leigh-Wood
Topics: Employment & Wages, Health care
BFI Working Paper·Apr 7, 2025

Mechanism Design for Personalized Policy: A Field Experiment Incentivizing Exercise

Rebecca Dizon-Ross and Ariel D. Zucker
Topics: Health care
BFI Working Paper·Mar 27, 2025

The Value of Medical Innovation in the Fight Against COVID-19 in the United States

Tomas Philipson, A. Mark Fendrick, Yier Ling, Eric Sun, and James Williams
Topics: Health care